Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

PR Newswire July 12, 2022

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 12, 2022

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

PR Newswire March 29, 2022

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

PR Newswire March 21, 2022

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

PR Newswire March 17, 2022

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

PR Newswire March 1, 2022

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

PR Newswire February 24, 2022

Pulmatrix Issues Letter to Stockholders

PR Newswire February 1, 2022

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

PR Newswire December 17, 2021

Pulmatrix Announces $6.75 Million Registered Direct Offering

PR Newswire December 15, 2021

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

PR Newswire November 10, 2021

Pulmatrix Announces Resolution of Contract Dispute with Cipla

PR Newswire November 9, 2021

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

PR Newswire August 10, 2021

Pulmatrix appoints Director Anand Varadan

PR Newswire July 27, 2021

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

PR Newswire May 11, 2021

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

PR Newswire April 15, 2021

Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

PR Newswire April 12, 2021

Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

PR Newswire April 12, 2021

Pulmatrix Reports 2020 Financial Results and Provides Business Update

PR Newswire March 23, 2021

Pulmatrix Provides a Pipeline and Business Update

PR Newswire March 4, 2021